IBA, Framatome Form Joint Venture to Produce Astatine — 211 for Cancer Therapies

IBA and Framatome formed Ekalia, a jointly owned venture to industrialize astatine-211 production for targeted cancer therapies. The venture plans a production network across Europe and North America, combining cyclotron technology with nuclear industrial expertise. Its first site in Nantes, France, is expected to become operational in 2028. A second pilot site is planned in the United States, followed by additional sites across Europe and the United States. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IBA — Ion Beam Applications SA published the original content used to generate this news brief on October 16, 2026, and is solely responsible for the information contained therein. (C)